Key result
Ranolazine, an approved late Na current blocker, produces antiarrhythmic effects in the atria and ventricle by inhibiting the abnormally enhanced late Na current seen in ischemia and heart failure.
Why the study?
Do late Na current blockers like ranolazine produce antiarrhythmic effects in pathological conditions such as ischemia and heart failure?
Do late Na current blockers like ranolazine produce antiarrhythmic effects in pathological conditions such as ischemia and heart failure?
Ranolazine and other late Na current blockers offer therapeutic antiarrhythmic potential by inhibiting the abnormally enhanced late Na current in conditions like ischemia and heart failure.
Answers are grounded in this paper and cite their sources.
This review highlights ranolazine's potential off-label utility for arrhythmias in ischemic heart disease.
The purpose of this article is to review the basis of arrhythmogenesis, the functional and clinical role of the late Na current, and its therapeutic inhibition. Under pathological conditions such as ischemia and heart failure this current is abnormally enhanced and influences cellular electrophysiology as a proarrhythmic substrate in myocardial pathology. Ranolazine the only approved late Na current blocker has been demonstrated to produce antiarrhythmic effects in the atria and the ventricle. We summarize recent experimental and clinical studies of ranolazine and other experimental late Na current blockers and discuss the significance of the available data.
No takes yet. Share an insight, caveat, or question.
Mason et al. (2016) conducted a review in Arrhythmia, ischemia, and heart failure. Ranolazine and other late Na current blockers was evaluated. Ranolazine, an approved late Na current blocker, produces antiarrhythmic effects in the atria and ventricle by inhibiting the abnormally enhanced late Na current seen in ischemia and heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: